Jennison Associates’s Maravai LifeSciences MRVI Stock Holding History

Jennison Associates’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,990,414	Closed	-$16.3M	–	618
2024 Q4	$16.3M	Buy	2,990,414 +9,769	+0.3%	+$62.9K	0.01%	359
2024 Q3	$24.8M	Sell	2,980,645 -1,574,052	-35%	-$13.6M	0.02%	322
2024 Q2	$32.6M	Buy	4,554,697 +4,160,803	+1,056%	+$35.9M	0.02%	279
2024 Q1	$3.42M	Buy	+393,894	New	+$2.66M	﹤0.01%	444
2023 Q4	–	Sell	-2,547,753	Closed	-$25.5M	–	608
2023 Q3	$25.5M	Buy	2,547,753 +769,362	+43%	+$8.45M	0.02%	285
2023 Q2	$22.1M	Hold	1,778,391	–	–	0.02%	305
2023 Q1	$24.9M	Buy	1,778,391 +343,464	+24%	+$4.93M	0.02%	298
2022 Q4	$20.5M	Buy	+1,434,927	New	+$22.6M	0.02%	320
2021 Q1	–	Sell	-265,386	Closed	-$7.44M	–	715
2020 Q4	$7.44M	Buy	+265,386	New	+$7.39M	0.01%	434

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates's MRVI Position: Q1 2025 in Review

Jennison Associates sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 2,990,414 shares — an estimated $16.3M sold.

Jennison Associates first reported a position in MRVI in Q4 2020 and held it in 9 quarters. The position peaked at $32.6M in Q2 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

Jennison Associates reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
Jennison Associates sold 2,990,414 Maravai LifeSciences shares in Q1 2025, an estimated $16.3M.
Jennison Associates first reported a position in Maravai LifeSciences in Q4 2020 and held it in 9 quarters.
Jennison Associates's Maravai LifeSciences position peaked at $32.6M in Q2 2024.
184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Jennison Associates's 13F filing for Q1 2025, filed 5 May 2025.